MicroRNA expression profiles predict progression and clinical outcome in lung adenocarcinoma.
Lung cancer is one of the leading causes of cancer death worldwide. Accumulating evidence has indicated that microRNAs (miRNAs) can be proposed as promising diagnostic and prognostic markers for various cancers. The current study analyzed the miRNA expression profiles of 418 lung adenocarcinoma (LUAD) cases obtained from The Cancer Genome Atlas dataset, with the aim to investigate the relationship of miRNAs with progression and prognosis of LUAD. A total of 185 miRNAs were found to be differentially expressed between LUAD tumor tissues and adjacent normal tissues. Among them, 13, 10, 0, and 10 miRNAs were discovered to be associated with pathologic T, N, M, and Stage, respectively. Interestingly, mir-200 family (mir-200a, mir-200b, and mir-429) was shown to play a critical role in the progression of LUAD. In the multivariate Cox regression analysis, mir-1468 (P=0.009), mir-212 (P=0.026), mir-3653 (P=0.012), and mir-31 (P=0.002) were significantly correlated with recurrence-free survival. With regard to overall survival, mir-551b (P=0.011), mir-3653 (P=0.016), and mir-31 (P=0.001) were proven as independent prognostic markers. In summary, this study identified the cancer-specific miRNAs that may predict the progression and prognosis of LUAD.
Central Laboratory, Nanjing First Hospital, Nanjing Medical University.
Kang
K
Lin
Central Laboratory, Nanjing First Hospital, Nanjing Medical University.
Tao
T
Xu
Central Laboratory, Nanjing First Hospital, Nanjing Medical University.
Bang-Shun
BS
He
Central Laboratory, Nanjing First Hospital, Nanjing Medical University.
Yu-Qin
YQ
Pan
Central Laboratory, Nanjing First Hospital, Nanjing Medical University.
Hui-Ling
HL
Sun
Medical School, Southeast University, Nanjing, Jiangsu, People's Republic of China.
Hong-Xin
HX
Peng
Medical School, Southeast University, Nanjing, Jiangsu, People's Republic of China.
Xiu-Xiu
XX
Hu
Central Laboratory, Nanjing First Hospital, Nanjing Medical University.
Shu-Kui
SK
Wang
lung adenocarcinoma; microRNA; prognosis; progression
Clin Cancer Res. 2016 Jan 1;22(1):218-29
26265693
Cancer Inform. 2008;6:9-15
19259398
Cancer Cell. 2006 Mar;9(3):189-98
16530703
RNA Biol. 2008 Jul-Sep;5(3):115-9
19182522
Cancer Lett. 2013 Feb 1;329(1):84-90
23111103
Gastroenterol Res Pract. 2013;2013:804128
24204382
Tumour Biol. 2014 Nov;35(11):11639-45
25139099
Med Oncol. 2014 Oct;31(10):203
25192889
Cancer Lett. 2014 Mar 28;344(2):166-73
24262661
Tumour Biol. 2015 Dec;36(12):9327-37
26104764
Br J Cancer. 2014 Mar 18;110(6):1614-21
24504363
Mol Oncol. 2012 Dec;6(6):590-610
23102669
Nature. 2005 Jun 9;435(7043):834-8
15944708
Mol Biol Cell. 2012 Apr;23 (8):1423-34
22357618
J Transl Med. 2014 Jun 04;12:159
24893932
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
26808342
Gynecol Oncol. 2009 Sep;114(3):457-64
19501389
Int J Oncol. 2015 Dec;47(6):2141-52
26459797
Br J Cancer. 2015 Nov 3;113(9):1358-66
26393886
Cancer Cell. 2008 Jan;13(1):48-57
18167339
Am J Transl Res. 2015 Nov 15;7(11):2519-26
26807196
CA Cancer J Clin. 2015 Mar;65(2):87-108
25651787
Cell. 2004 Jan 23;116(2):281-97
14744438
Lancet Oncol. 2015 Jul;16(7):e342-51
26149886
Nature. 2014 Jul 31;511(7511):543-50
25079552
Nat Rev Cancer. 2006 Nov;6(11):857-66
17060945
Clin Cancer Res. 2013 Oct 1;19(19):5423-33
23946296
Cancer Biol Ther. 2010 Aug 1;10(3):219-22
20592490
Medicine (Baltimore). 2015 Apr;94(16):e767
25906110
Carcinogenesis. 2012 Jun;33(6):1126-33
22491715
PLoS One. 2015 Jun 05;10(6):e0128628
26046780
Tumour Biol. 2015 Sep;36(10):8159-66
25990459
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
26742998
PLoS One. 2014 Jul 16;9(7):e101802
25028925
Cancer Res. 2010 May 1;70(9):3638-46
20388802